LSE:AZNPharmaceuticals
AstraZeneca (LSE:AZN) Signs Global Precision Oncology Diagnostics Alliance
AstraZeneca (LSE:AZN) announced a global alliance with SOPHiA GENETICS to co-develop and commercialize decentralized companion diagnostics for precision oncology therapies.
The SOPHiA GENETICS partnership is intended to expand access to advanced cancer diagnostics and support targeted treatment decisions across multiple markets.
AstraZeneca also entered a new collaboration with Pathos AI focused on advancing an investigational breast cancer therapy using data driven clinical development...